Profile
| Metric | Value |
|---|---|
| Full Name | Solventum Corporation |
| Ticker | NYSE: SOLV |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Country | United States |
| IPO | |
| Indexes | |
| Website | solventum.com |
| Employees | 22,000 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $85.77 | |
| Price, 1D Change | +1.82% | |
| Market Cap | $15B | |
| - | ||
| PE Ratio | 9.87 | |
| Beta | 0.91 | |
| Revenue | $8B | |
| Revenue, 1Y Change | +0.70% | |
| EPS | $2.76 | |
| EPS, 1Y Change | -64.62% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | SOLV.V | |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | $2.76 | |
| EPS Estimate | $6.02 | |
| EPS Est. Change | +118.37% | |
| Revenue | $8.25B | |
| Revenue Estimate | $8.27B | |
| Revenue Est. Change | +0.23% | |
| Current Price | $85.77 | |
| Price Target | - | $85.00 |
| Price Tgt. Change | - | -0.90% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $6.57 | $2.76 | -58.00% | |
| $6.02 | N/A | +118.37% | |
| $6.36 | N/A | +130.71% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $8.23B | $8.25B | +0.28% | |
| $8.27B | N/A | +0.23% | |
| $7.98B | N/A | -3.31% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +24.38% | |
| Price, 3Y | - | |
| Market Cap, 1Y | +24.85% | |
| Market Cap, 3Y | - | |
| Revenue, 1Y | +0.70% | |
| Revenue, 3Y | +1.02% | |
| EPS, 1Y | -64.62% | |
| EPS, 3Y | -67.38% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $85.77 | |
| SMA 200 | $73.86 | |
| SMA 200 vs Price | -13.89% | |
| SMA 50 | $78.81 | |
| SMA 50 vs Price | -8.11% | |
| Beta | 0.91 | |
| ATR | $1.70 | |
| 14-Day RSI | 68.44 | |
| 10-Day Volatility | 21.45% | |
| 1-Year Volatility | 32.05% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $8.25B | |
| EPS | $2.76 | |
| Gross Profit | $4.59B | |
| Gross Margin | 55.65% | |
| Operating Profit | $1.04B | |
| Operating Margin | 12.55% | |
| Net Income | $479.00M | |
| Net Margin | 5.80% | |
| EBITDA | $1.53B |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 2.77 | |
| Current Ratio | 1.20 | |
| Quick Ratio | 0.84 | |
| - | ||
| F-Score | 7 | |
| Altman Z-Score | 1.64 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | 9.87 | |
| PS Ratio | 1.77 | |
| PB Ratio | 2.98 | |
| EV/EBITDA | 10.16 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $2.96B | |
| Cash & Equivalents | $762.00M | |
| Total Assets | $14.46B | |
| Current Assets | $3.25B | |
| Total Liabilities | $11.50B | |
| Current Liabilities | $2.70B | |
| Total Debt | $8.18B | |
| Short Term Debt | $287.00M | |
| Accounts Payable | $618.00M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $7.22B | |
| Operating Expenses | $3.56B | |
| Cost Of Goods Sold | $3.66B | |
| SG&A | $2.78B | |
| D&A | $555.00M | |
| Interest Expense | $0.00 | |
| Income Tax | $127.00M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | $1.19B | |
| CFI | -$380.00M | |
| CFF | -$240.00M | |
| Capex | $380.00M | |
| Free Cash Flow | $805.00M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| BTIG | → | |
| UBS | → | |
| Piper Sandler | → | |
| UBS | ||
| Wells Fargo | → | |
| Jefferies | ||
| Wells Fargo | → | |
| Piper Sandler | → | |
| Morgan Stanley | → | |
| Argus Research | → |
Analyst sentiment
Institutional ownership
Screeners with SOLV
Data Sources & References
- SOLV Official Website www.solventum.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1964738/000196473825000091/0001964738-25-000091-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1964738/000196473825000019/0001964738-25-000019-index.htm
- List of S&P 500 Companies www.spglobal.com/spdji/en/indices/equity/sp-500/#overview
- SOLV Profile on Yahoo Finance finance.yahoo.com/quote/SOLV
- SOLV Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/solv
FAQ
What is the ticker symbol for Solventum Corporation?
The ticker symbol for Solventum Corporation is NYSE:SOLV
Does Solventum Corporation pay dividends?
No, Solventum Corporation does not pay dividends
What sector is Solventum Corporation in?
Solventum Corporation is in the Healthcare sector
What industry is Solventum Corporation in?
Solventum Corporation is in the Medical Instruments & Supplies industry
What country is Solventum Corporation based in?
Solventum Corporation is headquartered in United States
When did Solventum Corporation go public?
Solventum Corporation initial public offering (IPO) was on April 1, 2024
Is Solventum Corporation in the S&P 500?
Yes, Solventum Corporation is included in the S&P 500 index
Is Solventum Corporation in the NASDAQ 100?
No, Solventum Corporation is not included in the NASDAQ 100 index
Is Solventum Corporation in the Dow Jones?
No, Solventum Corporation is not included in the Dow Jones index
When was Solventum Corporation last earnings report?
Solventum Corporation's most recent earnings report was on November 6, 2025
When does Solventum Corporation report earnings?
The next expected earnings date for Solventum Corporation is February 26, 2026